The European Leadership Summit on Chronic Care, Amsterdam, The Netherlands

3-4 December, 2007, Amsterdam, The Netherlands
Organised under the high patronage of the European Commission, the event will convene senior executives from key organisations advancing chronic care in Europe including providers, payers, suppliers, customers, policy-makers and health officials.

The European Leadership Summit on Chronic Care is the forum where government and industry leaders share successful initiatives and best practices. So far, the agenda includes case studies from 12 different countries.

Through the support of our partner organizations, we are creating a truly international event, reaching key health leaders in over 40 countries. An international delegation will enjoy this two-day networking opportunity, featuring visionary keynote addresses, controversial debates, implementation case studies, tutorials and informal roundtable discussions.

Four focused summits will give attendees a unique opportunity to discuss pertinent issues in depth and determine actionable plans with their colleagues:

  • IT Infrastructures, Electronic Health Records and Chronic Care
  • Aligning Financial Incentives and Restructuring Care
  • Telehealth and Remote Monitoring
  • Empowering Patients and Supporting Self-Care

Two best practice seminars will also explore disease specific initiatives for:

  • Diabetes
  • Cardiovascular and Lung Diseases

For further information and registration, please visit: http://www.worldcongress.com/events/HL07080/

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...

Pfizer and Astellas amend clinical research protoc…

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced amendments to the protocols for two registratio...